Lantern Pharma Inc.
NASDAQ:LTRN

Watchlist Manager
Lantern Pharma Inc. Logo
Lantern Pharma Inc.
NASDAQ:LTRN
Watchlist
Price: 3.11 USD 1.97%
Market Cap: 33.5m USD

Intrinsic Value

LTRN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one LTRN stock under the Base Case scenario is 2.23 USD. Compared to the current market price of 3.11 USD, Lantern Pharma Inc. is Overvalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LTRN Intrinsic Value
2.23 USD
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Lantern Pharma Inc.

Valuation History Unavailable

Historical valuation for LTRN cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Lantern Pharma Inc.
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lantern Pharma Inc.

Current Assets 20.8m
Cash & Short-Term Investments 19.7m
Other Current Assets 1.1m
Non-Current Assets 272.9k
PP&E 236.2k
Other Non-Current Assets 36.7k
Efficiency

Free Cash Flow Analysis
Lantern Pharma Inc.

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Lantern Pharma Inc.

Revenue
0 USD
Operating Expenses
-21.3m USD
Operating Income
-21.3m USD
Other Expenses
1.4m USD
Net Income
-19.9m USD
Fundamental Scores

LTRN Profitability Score
Profitability Due Diligence

Lantern Pharma Inc.'s profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional ROIC
ROIC is Increasing
Negative Free Cash Flow
47/100
Profitability
Score

Lantern Pharma Inc.'s profitability score is 47/100. The higher the profitability score, the more profitable the company is.

LTRN Solvency Score
Solvency Due Diligence

Lantern Pharma Inc.'s solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Lantern Pharma Inc.'s solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LTRN Price Targets Summary
Lantern Pharma Inc.

Wall Street analysts forecast LTRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LTRN is 22.44 USD with a low forecast of 15.15 USD and a high forecast of 27.3 USD.

Lowest
Price Target
15.15 USD
387% Upside
Average
Price Target
22.44 USD
622% Upside
Highest
Price Target
27.3 USD
778% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Lantern Pharma Inc.
does not pay dividends
Shareholder Yield

Current shareholder yield for LTRN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

LTRN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one LTRN stock?

The intrinsic value of one LTRN stock under the Base Case scenario is 2.23 USD.

Is LTRN stock undervalued or overvalued?

Compared to the current market price of 3.11 USD, Lantern Pharma Inc. is Overvalued by 28%.

Back to Top